Journal article

Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?

Gemma Reynolds, Gabrielle Haeusler, Monica A Slavin, Benjamin Teh, Karin Thursky



PURPOSE: Contention surrounds how best to screen patients for latent and undiagnosed infection prior to cancer treatment. Early treatment and prophylaxis against reactivation may improve infection-associated morbidity. This study sought to examine rates of screening and prevalence of latent infection in overseas-born patients receiving cancer therapies. METHODS: A single-centre retrospective audit of 952 overseas-born patients receiving chemotherapy, targeted agents and immunotherapy between January 1 and December 31 2019 was undertaken at Peter MacCallum Cancer Centre. Pre-treatment screening for hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), latent tuberculosis (..

View full abstract


Awarded by National Health and Medical Research Council

Funding Acknowledgements

B.W.T is supported by the Australian Government National Health and Medical Research Council Early Career Fellowship, Medical Research Future Fund Emerging Leader Fellowship and Peter MacCallum Foundation Discovery Partner Fellowship. B.W.T has received research funding from Merck Sharp and Dohme, Gilead Sciences and Sanofi-Pasteur and on the advisory board for CSLBehring. M.A.S. is supported by National Health and Medical Research Council grants 1116876 and 1173791. M.A.S. has received research funding from Merck, F2G, and Gilead, and personal fees from Pfizer and Gilead.